Results 101 to 110 of about 112,411 (265)
Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel +5 more
wiley +1 more source
The General Disease Factor (“d”): First Empirical Evidence From China
Med Research, EarlyView.
Hongyi Sun +4 more
wiley +1 more source
ABSTRACT Background/Objectives Post‐inflammatory hyperpigmentation (PIH) is a frequent sequela of acne in patients with skin of colour (SOC). While sunscreen is widely recommended for PIH prevention, little is known about real‐world sunscreen practices in this group. This study aimed to evaluate sunscreen use, barriers and factors influencing adherence
Xiaozhun Hang, Davin Sui Lim, Lisa Byrom
wiley +1 more source
Hand eczema is a common allergic disease characterized by a chronic relapsing course with a 15% lifetime prevalence. Human immunodeficiency virus-infected individuals have a higher risk of Staphylococcus aureus infection which is associated with the ...
Dongmei Chen, Wei Liu, Yanxi Li
doaj +1 more source
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim +7 more
wiley +1 more source
Reacciones cutáneas a sensores de glucosa: presente y futuro
F.J. Navarro-Triviño
doaj +1 more source
ABSTRACT Background Skin disease is a major cause of morbidity in Australia and a leading reason for primary care visits. Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of skin conditions but face barriers to accessing culturally safe specialist services.
Nikhil Dwivedi +6 more
wiley +1 more source
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau +22 more
wiley +1 more source
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier +221 more
wiley +1 more source

